Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01007942
First received: November 2, 2009
Last updated: February 20, 2017
Last verified: February 2017
  Purpose
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free survival and over survival in HER2/neu positive women with locally advanced or metastatic breast cancer who are resistant to trastuzumab and have been pre-treated with a taxane.

Condition Intervention Phase
HER2/Neu Over-expressing Locally Advanced Breast Cancer
Metastatic Breast Cancer
Drug: everolimus
Drug: Placebo
Drug: vinorelbine
Drug: trastuzumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.

Resource links provided by NLM:


Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Progressive-free Survival (PFS) Per Investigator Assessment [ Time Frame: Every 6 weeks until disease progression or death which ever occurred first up to about 41 months ]
    PFS was defined as the time from the date of randomization to the date of first radiologically documented tumor progression or death from any cause, whichever occurs first. PFS primary analysis performed when 415 events were reached. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.


Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: Every 3 months until death up to 41 months ]
    OS was defined as the time from date of randomization to the date of death from any cause. Final OS was conducted when 388 deaths occurred.

  • Overall Response Rate (ORR) [ Time Frame: Every 6 weeks until disease progression or death which ever occurred first up to about 41 months ]
    ORR was defined as the percentage of participants whose best overall response was either complete response (CR) or partial response (PR) according to RECIST version 1.0. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

  • Clinical Benefit Rate (CBR) [ Time Frame: Every 6 weeks until disease progression or death which ever occurred first up to about 41 months ]
    CBR was defined as the percentage of participants whose best overall response, according to RECIST, was either complete response (CR), a partial response (PR) or stable disease (SD) lasting for at least 24 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; SD = Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD; PD = At least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline.

  • Median Time to Deterioration of the ECOG Performance Status Score [ Time Frame: baseline, until disease progression or death up to about 41 months ]
    Time to deterioration of ECOG performance status score was summarized at time of assessment. ECOG (Eastern Cooperative Oncology Group)performance scale is a standard criteria for measuring how treatment of cancer impacts their level of functioning in terms of their ability to care for themselves, daily activity, & physical ability (walking, working, etc.). Scale score ranges from 0 to 5, 5 being the worst. ECOG scale index: 0 - Fully active, able to carry on all pre-disease performance without restriction. 1 - Restricted in physically strenuous activity but ambulatory & able to carry out work of a light or sedentary nature, e.g., light housework, office work. 2 - Ambulatory & capable of all self-care but unable to carry out any work activities. Up & about more than 50% of waking hours. 3 - Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4 - Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5 - Dead

  • PRO: Time to Deterioration in Global Health Status/QoL Domain Score of the European Organization for the Research and Treatment of Cancer (EORTC)-Core Quality of Life Questionnaire (QLQ-C30) (by at Least 10%) [ Time Frame: Baseline, until disease progression or death up to about 41 months ]
    PRO = patient reported outcomes; Time to deterioration (≥ 10% worsening from baseline), in the global health status of EORTC QLQ-C30 scale was done in the 3 functional scales (emotional, physical, & social functioning [EF, PF, & SF]). It contains 30 items & is composed of multi-item scales & single-item measures. These include 5 functional scales (physical, role, emotional, social & cognitive functioning), 3 symptom scales (fatigue, pain, nausea, & vomiting), a global health status/QoL scale, and 6 single items (dyspnea, diarrhea, constipation, anorexia, insomnia & financial impact). Each of the multi-item scale includes a different set of items - no item occurs in more than 1 scale. Each item in the EORTC QLQ-C30 has 4 response categories (1=Not at all, 2= A little, 3= Quite a bit, 4= Very much) with the higher number representing a worse outcome. The global health domain score of the QLQ-C30 questionnaire was pre-specified as the primary QoL domain of interest & disclosed here.

  • Everolimus Blood Concentrations by Leading Dose and Time Point [ Time Frame: Cycle 2, Day 1 ]
    Pre-dose (Cmin) and 2 hours post-dose (C2h) everolimus PK blood samples were collected at Cycle 2 Day 1. Only valid everolimus PK blood samples collected at steady state were used in the analyses.

  • Vinorelbine Blood Concentrations by Leading Dose and Time Point [ Time Frame: Cycle 2, Day 1 ]
    Pre-infusion (Cmin) and end of infusion (C2h) vinorelbine PK blood samples were collected at Cycle 2 Day 1. Only valid vinorelbine PK blood samples collected at steady state were used in the analyses.

  • Trastuzumab Blood Concentrations by Leading Dose and Time Point [ Time Frame: Cycle 3, Day 1 ]
    Pre-infusion (Cmin) and end of infusion (C2h) trastuzumab PK blood samples were collected at Cycle 3 Day 1. Only valid trastuzumab PK blood samples collected at steady state were used in the analyses.


Enrollment: 569
Study Start Date: October 2009
Study Completion Date: June 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everolimus + vinorelbine + trastuzumab
Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
Drug: everolimus
Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
Other Name: RAD001
Drug: vinorelbine
intravenous vinorelbine (25 mg/m2 weekly)
Drug: trastuzumab
intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
Placebo Comparator: placebo + vinorelbine + trastuzumab
Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only
Drug: Placebo
Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
Drug: vinorelbine
intravenous vinorelbine (25 mg/m2 weekly)
Drug: trastuzumab
intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.
  • HER2+ status defined as IHC 3+ staining or in situ hybridization positive
  • Patients with resistance to trastuzumab
  • Prior taxane therapy
  • Patients with an ECOG performance status of 0 - 2
  • Patients with measurable disease as per RECIST criteria
  • Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study;
  • Patients must meet laboratory criteria defined in the study within 21 days prior to randomization

Exclusion Criteria:

  • Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer
  • More than three prior chemotherapy lines for advanced disease.
  • Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
  • Peripheral neuropathy ≥ grade 2 at randomization
  • Active cardiac disease
  • History of cardiac dysfunction
  • Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer
  • Known hypersensitivity to any study medication
  • Breastfeeding or pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01007942

  Hide Study Locations
Locations
United States, Arizona
University of Arizona / Cancer Center AZ Onc Assoc
Tucson, Arizona, United States, 85724
University of Arizona / Cancer Center Deptof Uof A/Arizona Cancer(3)
Tucson, Arizona, United States, 85724
United States, California
University of California San Diego - Moores Cancer Center La Jolla - UCSD Moores Cancer
La Jolla, California, United States, 92093-0658
United States, Colorado
Rocky Mountain Cancer Centers RMCC
Greenwood Village, Colorado, United States
United States, District of Columbia
Georgetown University/Lombardi Cancer Center Dept.of Lombardi CancerCtr (3)
Washington, District of Columbia, United States, 20007-2197
United States, Florida
Comprehensive Cancer Center - Boca Raton Deerfield Beach
Boca Raton, Florida, United States, 33248
Comprehensive Cancer Center - Boca Raton Dept.of BocaRatonCompCanCtr
Boca Raton, Florida, United States, 33248
Florida Cancer Specialists DeptofFloridaCancerSpecialists
Fort Myers, Florida, United States, 33916
Memorial Hospital Memorial Cancer Institute
Hollywood, Florida, United States, 33021
MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2)
Orlando, Florida, United States, 32806
United States, Georgia
Emory University School of Medicine/Winship Cancer Institute Dept.of WinshipCancerInst. (2)
Atlanta, Georgia, United States, 30322
United States, Illinois
North Shore University Health System NSU
Evanston, Illinois, United States, 60201
United States, Kansas
Kansas City Cancer Center KCCC- South (2)
Overland Park, Kansas, United States, 66210
United States, Maryland
Maryland Oncology Hematology
Owning Mills, Maryland, United States, 21117,
United States, Minnesota
Park Nicollet Institute Dept. of Park Nicollet
St. Louis Park, Minnesota, United States, 55416
United States, Missouri
St. Louis University Cancer Center SLU Cancer Center
St. Louis, Missouri, United States, 63110
United States, Nebraska
University of Nebraska Medical Center Unv Nebraska Med Ctr (2)
Omaha, Nebraska, United States, 68198
United States, Nevada
Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4)
Las Vegas, Nevada, United States, 89109
Nevada Cancer Institute Dept. of Nevada Cancer (3)
Las Vegas, Nevada, United States, 89135
United States, New Jersey
Overlook Hospital - Carol G Simon Cancer Center Carol G Simon
Summit, New Jersey, United States, 07901
United States, New York
Clinical Research Alliance Dept.ofArenaOncologyAssoc(2)
Lake Success, New York, United States, 11042
United States, North Carolina
Duke University Medical Center Dept. of DUMC (2)
Durham, North Carolina, United States, 27710
United States, Oregon
Northwest Cancer Specialists Tutlatin
Portland, Oregon, United States, 97210
United States, Pennsylvania
University of Pittsburgh Cancer Institute DeptofMageeWomen'sHospital(2)
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
The Jones Clinic Dept .of The Jones Clinic (3)
Germantown, Tennessee, United States, 38138
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(6)
Nashville, Tennessee, United States, 37203
United States, Texas
Texas Cancer Center ( Medical City Dallas Hospital) Dept. of Texas Cancer Ctr. (2)
Dallas, Texas, United States, 75230
Texas Oncology Presbyterian Hospital (2)
Dallas, Texas, United States, 75246
Texas Oncology Texas Onc - Amarillo
Dallas, Texas, United States, 75246
Texas Oncology Texas Oncology - Sammons
Dallas, Texas, United States, 75246
Texas Oncology Midtown
Dallas, Texas, United States, 75251
University of Texas Southwestern Medical Center University of TX SW Med Ctr(2)
Dallas, Texas, United States, 75390-8852
University of Texas/MD Anderson Cancer Center SC-5
Houston, Texas, United States, 77030-4009
Baylor College of Medicine Baylor
Houston, Texas, United States, 77030
Longview Cancer Center Longview Cancer Center (2)
Longview, Texas, United States, 75601
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
San Antonio, Texas, United States, 78229
South Texas Oncology and Hematology, PA South Texas Oncology (2)
San Antonio, Texas, United States, 78258
Tyler Cancer Center Dept.ofTylerCancerCtr. (2)
Tyler, Texas, United States, 75702
United States, Utah
Utah Cancer Specialists Utah Cancer (2)
Salt Lake City, Utah, United States, 84106
United States, Virginia
Virginia Cancer Specialists Fairfax No.VA (2)
Fairfax, Virginia, United States, 22031
Virginia Oncology Associates Dept. of VOA (2)
Norfolk, Virginia, United States, 23502
United States, Washington
Swedish Cancer Institute Swedish Cancer Institute
Seattle, Washington, United States, 98104
United States, Wisconsin
Green Bay Oncology Green Bay Oncology
Green Bay, Wisconsin, United States, 54301
Argentina
Novartis Investigative Site
C A B A, Buenos Aires, Argentina, C1019ABS
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1050AAK
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina, 7600
Novartis Investigative Site
Quilmes, Buenos Aires, Argentina, B1878DVB
Novartis Investigative Site
Posadas, Misiones, Argentina
Novartis Investigative Site
Rosario, Sante Fe, Argentina, S200KZE
Novartis Investigative Site
Rio Negro, Viedma, Argentina, 8500
Novartis Investigative Site
Cordoba, Argentina, X5002AOQ
Novartis Investigative Site
Tucuman, Argentina, T4000IAK
Australia, New South Wales
Novartis Investigative Site
Kogarah, New South Wales, Australia, 2217
Novartis Investigative Site
St. Leonards, New South Wales, Australia, 2065
Australia, Queensland
Novartis Investigative Site
South Brisbane, Queensland, Australia, 4101
Novartis Investigative Site
Southport, Queensland, Australia, 4215
Australia, Tasmania
Novartis Investigative Site
Hobart, Tasmania, Australia, 7000
Australia, Victoria
Novartis Investigative Site
East Bentleigh, Victoria, Australia, 3165
Belgium
Novartis Investigative Site
Brussel, Belgium, 1090
Novartis Investigative Site
Bruxelles, Belgium, 1000
Novartis Investigative Site
Liège, Belgium, 4000
Novartis Investigative Site
Namur, Belgium, 5000
Novartis Investigative Site
Sint-Niklaas, Belgium, 9100
China, Shanghai
Novartis Investigative Site
Shanghai, Shanghai, China, 200032
China, Zhejiang
Novartis Investigative Site
Hangzhou, Zhejiang, China, 310022
China
Novartis Investigative Site
Beijing, China, 100021
Novartis Investigative Site
Beijing, China, 100039
Novartis Investigative Site
Guangzhou, China, 510060
Novartis Investigative Site
Shanghai, China, 200025
Czech Republic
Novartis Investigative Site
Novy Jicin, Czech Republic, 741 01
Novartis Investigative Site
Olomouc, Czech Republic, 775 20
Novartis Investigative Site
Prague 5, Czech Republic, 150 00
France
Novartis Investigative Site
Bayonne, France, 64100
Novartis Investigative Site
Besançon cedex, France, 25030
Novartis Investigative Site
Hyères, France, 83400
Novartis Investigative Site
La Chaussée St Victor, France, 41260
Novartis Investigative Site
La Roche sur Yon Cedex, France, 85925
Novartis Investigative Site
Nice Cedex 2, France, 06189
Novartis Investigative Site
Saint-Brieuc Cédex, France, 22015
Novartis Investigative Site
Villejuif Cedex, France, 94805
Germany
Novartis Investigative Site
Berlin, Germany, 14195
Novartis Investigative Site
Frankfurt, Germany, 60590
Novartis Investigative Site
Gerlingen, Germany, 70839
Novartis Investigative Site
Halle/Saale, Germany, 06120
Novartis Investigative Site
Hamburg, Germany, 20249
Novartis Investigative Site
Homburg, Germany, 66421
Novartis Investigative Site
Kiel, Germany, 24105
Novartis Investigative Site
Magdeburg, Germany, 39108
Novartis Investigative Site
Mainz, Germany, 55131
Novartis Investigative Site
Minden, Germany, 32429
Novartis Investigative Site
München, Germany, 80638
Novartis Investigative Site
Recklinghausen, Germany, 45657
Novartis Investigative Site
Velbert, Germany, 42551
Greece
Novartis Investigative Site
Athens, GR, Greece, 151 23
Novartis Investigative Site
Patra - RIO, GR, Greece, 265 04
Novartis Investigative Site
Thessaloniki, GR, Greece, 546 45
Novartis Investigative Site
Thessaloniki, GR, Greece, 564 03
Novartis Investigative Site
Athens, Greece, 18547
Novartis Investigative Site
Heraklion Crete, Greece, 711 10
Hungary
Novartis Investigative Site
Budapest, Hungary, 1062
Novartis Investigative Site
Budapest, Hungary, H-1122
Novartis Investigative Site
Debrecen, Hungary, 4032
Novartis Investigative Site
Gyor, Hungary, H-9023
Israel
Novartis Investigative Site
Jerusalem, Israel, 9112001
Novartis Investigative Site
Petach Tikva, Israel, 49100
Novartis Investigative Site
Ramat Gan, Israel, 5266202
Novartis Investigative Site
Tel Aviv, Israel, 6423906
Italy
Novartis Investigative Site
Catania, CT, Italy, 95125
Novartis Investigative Site
Milano, MI, Italy, 20132
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Milano, MI, Italy, 20157
Novartis Investigative Site
Pavia, PV, Italy, 27100
Novartis Investigative Site
Sondrio, SO, Italy, 23100
Japan
Novartis Investigative Site
Nagoya, Aichi, Japan, 464-8681
Novartis Investigative Site
Kashiwa, Chiba, Japan, 277-8577
Novartis Investigative Site
Maebashi-city, Gunma, Japan, 371-8511
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 003-0804
Novartis Investigative Site
Yokohama, Kanagawa, Japan, 241-8515
Novartis Investigative Site
Kumamoto City, Kumamoto, Japan, 860-8556
Novartis Investigative Site
Kyoto-city, Kyoto, Japan, 606-8507
Novartis Investigative Site
Suita-city, Osaka, Japan, 565-0871
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan, 113-8431
Novartis Investigative Site
Koto, Tokyo, Japan, 135-8550
Novartis Investigative Site
Fukuoka, Japan, 811-1395
Novartis Investigative Site
Osaka, Japan, 537-8511
Novartis Investigative Site
Osaka, Japan, 540-0006
Mexico
Novartis Investigative Site
Ciudad De Mexico, Distrito Federal, Mexico, 04980
Novartis Investigative Site
León, Guanajuato, Mexico, 37000
Poland
Novartis Investigative Site
Lublin, Poland, 20-090
Novartis Investigative Site
Warszawa, Poland, 02-781
Singapore
Novartis Investigative Site
Singapore, Singapore, 169610
Slovakia
Novartis Investigative Site
Bratislava, Slovakia, 83310
Novartis Investigative Site
Kosice, Slovakia, 040 91
Spain
Novartis Investigative Site
Cordoba, Andalucia, Spain, 14004
Novartis Investigative Site
Jaen, Andalucia, Spain, 23007
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41014
Novartis Investigative Site
Sabadell, Barcelona, Spain, 08208
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08036
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46009
Novartis Investigative Site
A Coruna, Galicia, Spain, 15009
Novartis Investigative Site
La Coruna, Galicia, Spain, 15006
Novartis Investigative Site
Majadahonda, Madrid, Spain, 28222
Novartis Investigative Site
La Laguna, Santa Cruz de Tenerife, Spain, 38320
Novartis Investigative Site
Barcelona, Spain, 08041
Novartis Investigative Site
Madrid, Spain, 28007
Novartis Investigative Site
Madrid, Spain, 28034
Novartis Investigative Site
Madrid, Spain, 28040
Novartis Investigative Site
Zaragoza, Spain, 50009
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10330
Novartis Investigative Site
Bangkok, Thailand, 10400
Novartis Investigative Site
Songkla, Thailand, 90110
Turkey
Novartis Investigative Site
Ankara, Turkey, 06100
Novartis Investigative Site
Fatih / Istanbul, Turkey, 34098
Novartis Investigative Site
Izmir, Turkey, 35040
United Kingdom
Novartis Investigative Site
Truro, Cornwall, United Kingdom, TR1 3LJ
Novartis Investigative Site
Surrey, England, United Kingdom, GU2 7XX
Novartis Investigative Site
Bournemouth, United Kingdom, BH7 7DW
Novartis Investigative Site
Leeds, United Kingdom, LS9 7TF
Novartis Investigative Site
London, United Kingdom, EC1A 7BE
Novartis Investigative Site
Manchester, United Kingdom, M20 4BX
Novartis Investigative Site
Plymouth, United Kingdom, PL6 8DH
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01007942     History of Changes
Other Study ID Numbers: CRAD001W2301
2008-008697-31 ( EudraCT Number )
Study First Received: November 2, 2009
Results First Received: June 10, 2016
Last Updated: February 20, 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Metastatic breast cancer
locally advanced breast cancer
HER2/neu positive breast cancer
HER2/neu over-expressing
progressive-free survival (PFS)
over survival (OS)
bolero
bolero 3
Breast cancer
everolimus
HER+
vinorelbine
herceptin
trastuzumab
RAD001

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Vinorelbine
Trastuzumab
Everolimus
Sirolimus
Vinblastine
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 25, 2017